Under the agreement, Cicel has committed to purchasing three Renaissance systems to pursue regulatory clearance from the State Food and Drug Administration in China and establish marketing activities there. The company expects regulatory clearance to take two years, and Cicel will have exclusive rights to market and distribute the system for the following three years.
More Articles on Orthopedic Devices:
TranS1 Reports 32% Drop in 4Q Revenue
Cleveland Clinic to Spin Off Orthopedic Preplanning Software
Titan Spine Expands to Europe With Subsidiary
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
